Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of alcohol (ethanol) and caffeine is commonly referred to as a "caffeinated alcoholic drink." This mixture combines a central nervous system depressant (alcohol) with a stimulant (caffeine). Caffeine acts primarily as an adenosine receptor antagonist in the brain, promoting alertness and wakefulness. Alcohol acts as an adenosine reuptake inhibitor and has sedative effects. When consumed together, caffeine can mask some of the sedative effects of alcohol without reducing actual intoxication or blood alcohol content. This masking effect may lead individuals to underestimate their level of impairment, increasing the risk for excessive drinking, injury, risky behaviors, dehydration, irregular heartbeat, higher blood pressure, and other health risks[1][2][4][5][6]. The combination has been associated with increased rates of binge drinking and adverse outcomes such as accidents or impaired driving[2][3]. Due to safety concerns—including increased risk-taking behavior—the U.S. FDA determined that adding caffeine to prepackaged alcoholic beverages was unsafe; most such products were removed from the market after 2010[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alcohol + caffeine.